Should You Buy GlaxoSmithKline plc Or Indivior plc Or Both?

Dave Sullivan assesses whether the future potential for GlaxoSmithKline plc (LON: GSK) and Indivior plc (LON: INDV) make them buys, despite static or lower dividends.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

London stocks ended the day down yesterday, mainly due to investors pausing for breath after a nice bounce from recent lows. At close the blue-chip index was off slightly at 6,139, well above the recent low of 5,537 at the close on 11 February.

Amongst the list of fallers were healthcare sector peers GlaxoSmithKline (LSE: GSK), off by 1.3% to 1,396p and Indivior (LSE: INDV), off by 2.1% to 166p. Now that both companies have released their final results, I’m weighing up whether the management teams are directing the businesses on the correct paths to profitable growth.

The chart says it all

It’s often the case that a quick look at a chart can give an indication as to the performance of the underlying business, and I think that this is the case here too. As we can see, Indivior has had a substantial fall from grace as investors headed for the exit following interim results in July and disappointment that the FDA didn’t approve the company’s Naloxone Nasal Spray, a new drug application for opioid overdose.

Also well off its recent highs, GlaxoSmithKline seems to have investors worried as management focuses on integrating the new businesses in Vaccines and Consumer Healthcare and restructure the Global Pharmaceuticals business.

Beating expectations but cancelling the dividend

I felt that the share price of Indivior had fallen too far, mainly due to a toxic combination of negative sentiment towards the industry in general following a campaign pledge from Presidential hopeful Hillary Clinton to crack down on rising prescription drug prices. She also plans to hold drug companies accountable so they get ahead by investing in research, not jacking up costs. General market volatility that has been around for a good six months now has also hit the shares.

However, the shares took a turn for the good, despite the company signalling that it would pass on future dividends once the final dividend was paid. It seems that this decision was taken due to the strategic decision to reinvest around an additional $35m in R&D and pre-commercialisation activity for launch of Buprenorphine Monthly Depot for opioid dependence.

Turning to valuation, analysts have again been required to upgrade their expectations for 2016 and 2017, which means that the shares now trade on a sub-11 times forecast earnings. This makes them look quite interesting to my mind.

A business in transition

I think that investors may be starting to warm to what could be a transformational new direction for GlaxoSmithKline. While 2015 earnings came in slightly above guidance, for the stock market, it’s all about the future, and this is where the management sounded rather bullish.

Management continued to expect double-digit constant currency growth, 80p in dividends for 2016 and 2017, and significant opportunities for the new R&D portfolio, of which approximately 80% has the potential to be first in class. In 2016/2017, development milestones are expected for assets such as: Shingrix, sirukumab, ICS/LABA/LAMA, cabotegravir, daprodustat and the Men ABCWY vaccine. In addition, it’s also expected that there will be up to 20 Phase 2 starts for assets in Immuno-inflammation, Oncology, Respiratory and Infectious diseases.

Following the results analysts have started to increase their earnings expectations, which is a key driver behind a company’s share price performance, and should analysts continue to upgrade their expectations, I would expect the share price to follow.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Surely, the Rolls-Royce share price can’t go any higher in 2025?

The Rolls-Royce share price was the best performer on the FTSE 100 in 2023 and so far in 2024. Dr…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

Here’s how an investor could start buying shares with £100 in January

Our writer explains some of the things he thinks investors on a limited budget should consider before they start buying…

Read more »

Investing Articles

Forget FTSE 100 airlines! I think shares in this company offer better value to consider

Stephen Wright thinks value investors looking for shares to buy should include aircraft leasing company Aercap. But is now the…

Read more »

Investing Articles

Are Rolls-Royce shares undervalued heading into 2025?

As the new year approaches, Rolls-Royce shares are the top holding of a US fund recommended by Warren Buffett. But…

Read more »

Investing Articles

£20k in a high-interest savings account? It could be earning more passive income in stocks

Millions of us want a passive income, but a high-interest savings account might not be the best way to do…

Read more »

Investing Articles

3 tried and tested ways to earn passive income in 2025

Our writer examines the latest market trends and economic forecasts to uncover three great ways to earn passive income in…

Read more »

Investing Articles

Here’s what £10k invested in the FTSE 100 at the start of 2024 would be worth today

Last week's dip gives the wrong impression of the FTSE 100, which has had a pretty solid year once dividends…

Read more »

Investing Articles

UK REITs: a once-in-a-decade passive income opportunity?

As dividend yields hit 10-year highs, Stephen Wright thinks real estate investment trusts could be a great place to consider…

Read more »